+35.5% · 90d
$22.48
-0.17 (-0.77%)
News
(1)March 2026
Bicara Therapeutics Inc. — 8-K Filing
BCAXBicara Therapeutics Inc.
# 🧾 What This Document Is This is a **combined 8-K filing and press release** from Bicara Therapeutics. It serves two major purposes: it officially reports their financial results for the end of 2025, and it gives a crucial update on the progress of their main drug, ficerafusp alfa. Think of it as
Read summaryView on SEC EDGAR
Peers in Biotechnology
VRTX#1
Vertex Pharmaceuticals Incorporated
$113.64B+0.64%
REGN#2
Regeneron Pharmaceuticals, Inc.
$78.80B-0.99%
ARGX#3
argenx SE
$49.22B+1.97%
ALNY#4
Alnylam Pharmaceuticals, Inc.
$42.61B-1.82%
ONC#5
BeOne Medicines AG
$34.75B+0.39%
INSM#6
Insmed Incorporated
$34.45B-0.37%
RPRX#7
Royalty Pharma plc
$27.86B+0.84%
BNTX#8
BioNTech SE
$23.26B-0.11%
ROIV#9
Roivant Sciences Ltd.
$20.38B+1.10%
MRNA#10
Moderna, Inc.
$20.34B-1.57%